Health Care
Health Care
J&J Buy of Aragon Deals a Blow to Medivation
Tickers in this article: JNJ MDVN
Medivation now has a formidable competitor for prostate cancer therapy.
06/17/13 - 09:57 AM EDT
MORE NEWS FOR HEALTH CARE
| Company | Last | %CHNG | Volume |
|---|---|---|---|
| Cytokinetics Inc (CYTK) | 1.89 | 29.45 | 13.82 M |
| USMD Holdings Inc (USMD) | 35.01 | 26.21 | 0.07 M |
| CombiMatrix Corporation (CBMX) | 2.95 | 16.14 | 1.53 M |
| Prothena Corporation PLC (PRTA) | 12.77 | 15.99 | 0.08 M |
| Infinity Pharmaceuticals Inc. (INFI) | 19.46 | 13.34 | 5.04 M |
| TG Therapeutics Inc (TGTX) | 7.19 | 11.13 | 0.49 M |
| Fibrocell Science Inc (FCSC) | 6.39 | 11.13 | 0.16 M |
| Staar Surgical (STAA) | 10.51 | 10.98 | 0.91 M |
| Cormedix Inc. (CRMD) | 0.93 | 9.42 | 0.17 M |
| Biodel Inc. (BIOD) | 4.76 | 8.43 | 1.50 M |
| Company | Last | %CHNG | Volume |
|---|---|---|---|
| GenMark Diagnostics Inc. (GNMK) | 9.57 | -12.76 | 1.86 M |
| MannKind Corporation (MNKD) | 6.60 | -12.40 | 38.07 M |
| Opexa Therapeutics Inc. (OPXA) | 1.49 | -11.31 | 0.61 M |
| Oramed Pharmaceuticals (ORMP) | 6.40 | -7.91 | 0.16 M |
| CardioNet Inc. (BEAT) | 5.64 | -7.69 | 1.70 M |
| Delcath Systems Inc. (DCTH) | 0.45 | -7.66 | 3.05 M |
| BG Medicine Inc. (BGMD) | 1.45 | -7.64 | 2.08 M |
| Tesaro Inc (TSRO) | 35.99 | -7.07 | 0.52 M |
| Biolase Inc (BIOL) | 3.98 | -7.01 | 0.91 M |
| Biota Pharmaceuticals Inc (BOTA) | 3.46 | 0.00 | 0.02 M |
| Company | Last | %CHNG | Volume |
|---|---|---|---|
| Pfizer Inc (PFE) | 29.40 | 0.82 | 160.35 M |
| MannKind Corporation (MNKD) | 6.60 | -12.40 | 38.07 M |
| Elan Corp PLC (ELN) | 13.78 | 2.15 | 24.82 M |
| Zoetis Inc (ZTS) | 31.18 | 0.71 | 24.29 M |
| Cytokinetics Inc (CYTK) | 1.89 | 29.45 | 13.82 M |
| Boston Scientific Inc. (BSX) | 9.54 | -1.04 | 12.21 M |
| Merck & Co Inc (MRK) | 47.75 | -0.10 | 11.82 M |
| Health Management Associates Inc. (HMA) | 16.32 | 1.62 | 9.09 M |
| Johnson & Johnson (JNJ) | 86.36 | 0.85 | 7.23 M |
| Bristol-Myers Squibb Company (BMY) | 46.85 | 0.88 | 7.16 M |
| Company | Last | %CHNG | Mkt Cap |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 86.36 | 0.85 | $240.5 B |
| Pfizer Inc (PFE) | 29.40 | 0.82 | $206.0 B |
| Novartis AG (NVS) | 73.12 | -0.23 | $180.1 B |
| Sanofi (SNY) | 54.56 | -0.84 | $147.6 B |
| Merck & Co Inc (MRK) | 47.75 | -0.10 | $144.3 B |
| GlaxoSmithKline PLC (GSK) | 52.47 | -0.51 | $129.7 B |
| Novo Nordisk A/S (NVO) | 161.87 | 0.11 | $88.9 B |
| Gilead Sciences Inc (GILD) | 51.94 | 1.78 | $77.8 B |
| Bristol-Myers Squibb Company (BMY) | 46.85 | 0.88 | $76.3 B |
| Amgen Inc (AMGN) | 101.50 | 2.44 | $74.3 B |
Featured Industry: Real Estate
-
People's United: Financial Winner
Bank stocks rose Tuesday amid expectations that the Federal Reserve will not hike rates anytime soon.
CBRE Group Inc (CBG): Today's Featured Real Estate Winner
RSI Alert For Tree.com (TREE)
The Deal: Weyerhaeuser Pares Gains Following $2.65 Billion Longview Deal
Too Much Selling Of Top Quartile Ranked Dividend Stock ACRE
Partner Headlines
-
Herbalife faces challenge of greater transparency over sales
-
Pharmaceutical groups face penalties for generic deals
-
Gene patent ruling hurts Myriad, but not fatally
-
Competing In The Sport Of Biotechs, Curis Takes Aim
-
Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study
-
Elan Is In Play
-
A.M. Best Affirms Aetna's Ratings - Analyst Blog
-
Abbott Progresses with Absorb in Japan - Analyst Blog
-
Encouraging Data on Novartis' Gilenya - Analyst Blog
-
Following The Data Leads Alkermes In Right Direction
PR / BWire
-
NTRR And Partners Explore The Cutting Edge Of $1.7 Billion U.S. Medical Marijuana Sector
-
AstraZeneca And Bristol-Myers Squibb Announce Top Line Results For SAVOR-TIMI-53 Cardiovascular Outcomes Trial Of Onglyza® (saxagliptin)
-
Protalix BioTherapeutics And Brazil's Ministry Of Health Enter Into Supply And Technology Transfer Agreement For UPLYSO(TM) (alfataliglicerase) In Brazil
-
Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
-
Intercept Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
-
Valeant Pharmaceuticals Prices Public Offering Of Common Shares
-
Faruqi & Faruqi, LLP Launches An Investigation Against OXiGENE, Inc. (OXGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
-
Lifshitz Law Firm Announces Investigation Of Belo Corp., Centerline Holding Company, Invacare Corporation And StellarOne Corporation
-
UCLA Presents Data On MediciNova's MN-166 In Methamphetamine Addiction At The 75th Annual Meeting Of The College On Problems Of Drug Dependence
-
Law Firm Finkelstein Thompson LLP Announces Investigation Of UPI Inc.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
Latest Market Update
04:44PM 06/18/13
NEW YORK (TheStreet) -- Major U.S. stock markets pushed higher Tuesday as investors anticipated that theFederal Reserve won't announce steps to aggressively curb the bond-buying program that has helped drive equities for more than a year.
The S&P 500 tacked on 0.78% to 1,651.80 while the Dow Jones Industrial Average gained 0.91% to 15,318.23. The Nasdaq popped 0.87% to 3,482.18.
The Fed began a two-day policy meeting today amid signs that inflation hasn't spiked as a result of the bank's stimulus measures, and data showing that the country's housing market remains months if not years away from a full recovery. ...
MoreBrokerage Partners
|
|
|
|
|
|
|
|
|
|
|
|